Save on Mirvetuximab Soravtansine-Gynx with Coupons, Discounts & Savings Programs

Mirvetuximab Soravtansine-Gynx is available as a 100 mg/20 mL (5 mg/mL) single-dose vial.

Mirvetuximab Soravtansine-Gynx is a targeted medication used to treat folate receptor-alpha (FRɑ) positive ovarian, fallopian tube, or primary peritoneal cancer that hasn’t responded well to other anticancer medications.

Mirvetuximab Soravtansine-Gynx is a antibody-drug conjugate (ADC). It’s a combination of a monoclonal antibody linked to a traditional chemotherapy medication that kills cancer cells. In Mirvetuximab Soravtansine-Gynx, the antibody portion (mirvetuximab) binds to the folate receptor-alpha protein found on cancer cells. Once that happens, Mirvetuximab Soravtansine-Gynx is absorbed into the cell. There, it releases a strong cancer-killing medication (soravtansine) that prevents the cells from dividing and growing, which leads to cell death.

The recommended dose of Mirvetuximab Soravtansine-Gynx is 6 mg/kg adjusted ideal body weight administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity.

Mirvetuximab Soravtansine-Gynx is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Mirvetuximab Soravtansine-Gynx:

• Vision and eye problems
• Fatigue
• Nausea
• Stomach pain
• Numbness and tingling of the hands or feet
• Diarrhea
• Constipation

Serious side effects are rare with Mirvetuximab Soravtansine-Gynx. Contact your healthcare provider immediately if you experience any of the following:

• Vision loss
• Serious lung problems: Difficulty breathing, trouble catching your breath, chest pain

The following medications may interact with Mirvetuximab Soravtansine-Gynx:

• Strong CYP3A4 Inhibitors: Closely monitor for Mirvetuximab Soravtansine-Gynx adverse reactions.

Various FDA-approved generic manufacturers

Based on its mechanism of action, Mirvetuximab Soravtansine-Gynx can cause harm to your unborn baby if taken when pregnant. Talk to your doctor if you are already pregnant or if you have plans on becoming pregnant. They will recommend what is best for you.

• Elahere